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Purpose. To evaluate the efficacy and safety of hyperbaric oxygen therapy (HBOT) in patients with acute retinal artery occlusion 
(RAO). Secondarily, to analyse the epidemiology and the clinical approach. Methods. Retrospective study of 13 patients submitted to 
HBOT between 2013 and 2018. e analysed parameters consisted of: systemic history, time between symptoms onset and treatment, 
initial approach, number of HBOT sessions, complications of HBOT and best corrected visual acuity—BCVA (of the total sample, 
central RAO—CRAO—group, and branch RAO—BRAO group). Results. Arterial hypertension was the most prevalent systemic 
risk factor (53.8%). Initial therapies were 100% normobaric oxygen administration, topical and oral hypotensive medication, eye 
massage and aspirin. CRAO was observed in 69.2% and BRAO in 30.8% of the cases, with clinically significant visual improvement 
(a decrease in logMAR of 0.3) in 55.5% and 75%, respectively. Time between symptoms onset and treatment had a median of 9 
hours. e median number of HBOT sessions was 7, without complications. Conclusions. HBOT provide BCVA improvement in 
patients with RAO, when it is performed in an early time aer the symptom onset. It seems to be an effective and safe therapeutic 
option for a pathology that still remains without approved treatment.
1. Introduction
Retinal artery occlusion (RAO) is a rare ophthalmological 
emergency, with embolism being the most common aetiology 
[1–4]. It is manifested by acute painless monocular vision loss 
and a meaningful visual improvement (three lines in Snellen 
chart) is expected only in 10% of the cases [1–7]. e time of 
ischemia is classically the critical prognosis factor for the 
visual outcome, considering that the retina is the tissue of the 
human body with the highest oxygen consumption, being 
therefore very sensitive to variations in oxygen [1, 4, 8, 9]. 
Animal models of central RAO (CRAO) have demonstrated 
that an ischemic insult to the retinal tissue greater than 90 
minutes (min) will lead to some degree of inner retina damage 
and it will be irreversible if greater than 240 min [10]. As 
opposed to animal models, in humans there is no clear time-
line until irreversible anoxic retinal damage occurs (some 
authors suggest elapsed time of around 6–6.5 hours, h) [11]. 
RAO remains without approved treatment and traditional 
options are not effective enough, having globally a nonsignif-
icant visual outcome improvement [4, 6].
Hyperbaric oxygen therapy (HBOT) delivers 100% oxygen 
by a pressure greater than 1 atmosphere (atm), increasing 
plasma oxygen transportation and diffusion, with positive 
effects in vascular perfusion and neuroprotection, in the 
presence of an adequate vascular supply. Its pathophysiological 
mechanisms are based on the retinal double vascular supply, 
in which the choroidal capillary vessels that supply the outer 
retina will bypass the occlusion and oxygenate inner ischemic 
retina until spontaneous reperfusion occurs [1, 2, 4, 8]. 
Normally, under normobaric conditions the choroidal circu-
lation supplies 60% of the oxygen needed by the retina, which 
increases to 100% under hyperbaric conditions [4]. HBOT 
also decrease edema and preserve compromised tissue adja-
cent to ischaemic area [1, 2, 8]. Karaman et al. demonstrated, 
in mice models of CRAO, that the apoptotic index of retinal 
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inner cells was lower in the group submitted to HBOT in the 
reperfusion phase than in control group [12]. Also in an ani-
mal experiment in a CRAO mice model, Gaydar et al. showed 
that HBOT diminished cell loss from 58% to 30%, which was 
related to increased survival of cells in the retinal inner 
layer [13]. According to the Tenth European Consensus 
Conference on Hyperbaric Medicine (2016), the European 
Committee of Hyperbaric Medicine (ECHM) indicate that 
CRAO cases have Type 2 recommendation (where HBOT is 
suggested, as it is supported by acceptable levels of evidence) 
and level C evidence (when the conditions do not allow for 
proper randomised controlled trials—RCTs—but there is 
ample and international expert consensus) [14]. e class of 
recommendation of HBOT by American College of 
Cardiology/American Heart Association (ACC/AHA) clinical 
practice guidelines is IIb (where it is not unreasonable to per-
form procedure/administer treatment) [15]. Also, Undersea 
and Hyperbaric Medicine Society (UHMS) refer that patients 
presenting CRAO within 24 h of symptom onset should be 
considered for HBOT [4].
e main purpose of this study was to evaluate the efficacy 
and the safety of HBOT in patients with RAO. e secondary 
purpose was to analyse the epidemiology and the clinical 
approach. e efficacy was evaluated by the: analyses of the 
best corrected visual acuity (BCVA) improvement, number of 
HBOT sessions and time between symptoms onset and HBOT. 
e safety was evaluated by the analyses of frequency and 
severity of complications.
2. Case Presentation
2.1. Methods. Retrospective study of 13 patients (13 eyes) 
with RAO from the Professor Doutor Fernando Fonseca E.P.E. 
Hospital (HFF, Lisbon, Portugal) were submitted to HBOT at 
the Underwater and Hyperbaric Medicine Center of the Armed 
Forces Hospital—Lisbon Pole, between September 2013 and 
June 2018. Inclusion criteria consisted of: RAO documented by 
fluorescein angiography; absence of patent cilioretinal artery; 
time between symptoms onset and treatment no longer than 
24 h; absence of previous ophthalmic pathology with relevant 
impact on BCVA; regular follow-up with documented BCVA; 
and tolerance to HBOT. All consecutive patients meeting the 
criteria during the period considered were included in the 
study and this was performed according to the principles of 
the Helsinki Declaration (2013).
Data was collected for the study through consultation of 
patients’ clinical records. e parameters studied were: demo-
graphic (patients’ age and sex) and epidemiological factors 
(personal systemic history, as dyslipidemia, arterial hyperten-
sion, diabetes, smoking habits, cerebrovascular or coronary 
disease, arrhythmia or other relevant factor for arterial occlu-
sion; and type of retinal occlusion between CRAO and branch 
RAO—BRAO); time between symptoms onset and treatment; 
the initial approach in the Emergency Room; number of 
HBOT sessions; complications of HBOT (frequency and 
severity); and BCVA (total sample, CRAO group and BRAO 
group). BCVA was analysed before and aer each session of 
HBOT, quantified initially in the Snellen chart in decimal scale 
and then converted to the logarithm of the minimal angle of 
resolution (logMAR) scale to perform the statistical analysis. 
In case of very low vision (<0.05 in Snellen chart), BCVA was 
assessed by semiquantitative scale, the capability to count-fin-
gers (CF), to see hand movement (HM) or light perception 
(LP) at a distance of 30 cm. Decimal value attributed to CF, 
HM and LP was 0.014, 0.005 and 0.0001, respectively, as 
described in some previous studies [2, 16]. A clinically 
significant visual improvement was defined as a decrease in 
logMAR of 0.3 [1, 2, 5].
e HBOT protocol applied had two phases: patients were 
initially submitted to two daily sessions of 100% oxygen at 
2.5 atm during 90 min during the first three consecutive days; 
then, patients were submitted to additional sessions (1 per 
day) if BCVA improvement occurred and until it stabilized, 
or the treatment was interrupted if no subjective BCVA gain 
occurred aer the first three consecutive sessions. is method 
followed the treatment algorithm of UHMS [4].
A statistical analysis was performed with the SPSS pro-
gram (Statistical Package for Social Sciences, version 22.0). 
Continuous variables were presented as median with mini-
mum and maximum values. Wilcoxon signed-rank test was 
applied to analyse the BCVA variation before and aer 
HBOT. A -value <0.05 was considered to be statistically 
significant.
2.2. Results
(a)  Demographic factors: the study included 13 eyes from 
13 patients, 8 males and 5 females, with a median age of 
70 years (min. 41; max. 83);
(b)  Epidemiological factors:
 (i)  Personal systemic history: arterial hypertension was 
the most prevalent (53.8%, number of patients— 
푛 = 7), followed by cerebrovascular disease (30.8%, 
푛 = 4), dyslipidemia (23.1%, 푛 = 3), coronary disease 
(7.7%, 푛 = 1), arrhythmia (7.7%, 푛 = 1) and smoking 
habits (7.7%, 푛 = 1);
(ii)  Type of retinal occlusion: CRAO was observed in 
69.2% (푛 = 9) of the cases and BRAO in 30.8% (푛 = 4);  
(c)  Time between symptoms onset and treatment: median of 
9 h (min. 2; max. 20), with 77% of cases up to 12 h;
(d)  e initial approach in the Emergency Room consisted of: 
administration of normobaric oxygen in 69.2% (푛 = 9), 
topical hypotensive application and oral acetazolamide in 
53.8% each (푛 = 7), and eye massage and oral administra-
tion of aspirin in 46.1% each (푛 = 6);
(e)  Number of HBOT sessions: median of 7 (min. 3; max. 
18), which corresponds to a total of 10.5 h of treatment;
(f)  Complications of HBOT: no complications were observed;
(g)  BCVA:
 (i)  Difference between pre and post-HBOT BCVA: there 
was a statistically significant improvement in BCVA 
of the total sample, the CRAO group and the BRAO 
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group, with this one having a better outcome, as 
detailed in Table 1 and Figure 1;
(ii)  Clinically significant improvement of BCVA: it was 
observed in 61.5% (푛 = 8) of cases in the total sam-
ple (푛 = 13). In the group of patients who improved 
(푛 = 8), 62.5% (푛 = 5) were patients with CRAO 
and 37.5% (푛 = 3) were patients with BRAO. ese 
results correspond also to an improvement in 55.5% 
(푛 = 5) of cases in the CRAO group (푛 = 9) and in 75% 
(푛 = 3) of cases in the BRAO group (푛 = 4). Best 
results were observed when HBOT was performed 
within 9 h of symptom onset. e detailed prevalence 
of BCVA subgroups (in decimal scale) for the total 
sample is shown in Figure 2.    
3. Discussion
According to our study, HBOT seems to be an effective and 
safe option in the treatment of patients with RAO, in case of 
an early administration. It may be an option to consider also 
because there is no approved treatment yet for RAO, the 
current alternative therapies do not have similar outcomes and 
without treatment there is little chance of visual improvement 
by the natural history [1, 2, 4].
e results of our study are in agreement with the literature 
and other studies, as patients responded well to HBOT, 
showing a clinically significant BCVA improvement in 61.5% 
(푛 = 8) of cases in the total sample, of which 62.5% (푛 = 5) 
belongs to the CRAO group and 37.5% (푛 = 3) belongs to the 
BRAO group [1, 2, 11, 17]. Coelho et al. observed a clinical 
significant BCVA improvement in 71.4% of the patients 
following HBOT and Hadanny et al. a BCVA improvement in 
67.2% [2, 11]. Hadanny et al. also demonstrated a significant 
mean improvement in BCVA (logMar) of 0.526 ± 0.688, from 
2.14 ± 0.50 to 1.61 ± 0.78 (푝 < 0.01), with 67% of the patients 
achieving a BCVA gain >0.3 logMar [11]. Also, an improvement 
from HM to CF has been described to be clinically relevant, 
and corresponds to an interval of 4 lines (in 0.1 log-unit steps) 
[2, 16]. Our results are in accordance with these. We observed 
an evolution of 31% of cases with LP to 0% aer treatment, 
15% of cases with HM to 7.7% and 23% to 15.4% of cases with 
CF.
e median number of HBOT sessions is also a parameter 
that contributes to the analysis of the efficacy of this therapeutic 
option. e median number of our study, which corresponds 
to a total of 10.5 h of treatment, is in line with what Wu et al. 
reported in his recent meta-analysis of seven randomized 
controlled trials (251 eyes, with the most effective treatment 
length over 9 hours) [6]. It is also noteworthy that, according 
to UHMS, the optimum number of HBOT sessions depends 
on the severity and duration of the patients’ symptoms and 
the degree of response to them. Most patients stabilize within 
1 week of symptom onset [4].
Our good results may be related to the early timing 
between symptoms and treatment (median of 9 h and 77% of 
cases within 12 h of symptom onset) and, the absence of other 
ophthalmic pathology. It is well known that the period of time 
until the treatment is considered the critical factor for the 
visual prognosis, between the several factors that may influence 
it. is is based on the main pathophysiological mechanism 
of an early HBOT, in case of RAO, of the hyperbaric oxygen 
Table 1: BCVA pre and post-HBOT (decimal and logaritmic scales; values in median with range—minimum and maximum values).
Total CRAO BRAO
BCVA pre-HBOT
Decimal scale 0.005 (min. 0.0001; max. 0.2) 0.005 (min. 0.0001; max. 0.014) 0.15 (min. 0.1; max. 0.2)
Logaritmic scale 2.3 (min. 4; max. 0.7) 2.3 (min. 4; max. 1.85) 0.82 (min.1; max. 0.7)
BCVA post-HBOT
Decimal scale 0.2 (min. 0.005; max. 1) 0.05 (min. 0.005; max. 1) 0.9 (min. 0.6; max. 1)
Logaritmic scale 0.7 (min. 2.3; max. 0) 1.3 (min. 2.3; max. 0) 0.045 (min. 0.22; max. 0)
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Figure 2: Prevalence of BCVA subgroups (in decimal scale) for the 
total sample.
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evolution of systemic vascular pathologies, thus implying a 
timely medical articulation with Internal Medicine, Cardiology 
and/or Neurology. e prevalence of vascular risk factors in 
our study is consistent with other studies, highlighting the 
arterial hypertension, dyslipidemia, and brain and cardiovas-
cular diseases [3, 23, 24].
ere are still few studies regarding this issue. Many of 
them have relatively small study samples and some of them 
differ not only in the definition of the ideal “time window” to 
perform HBOT but also on the HBOT protocol, regarding 
that there is no consensus for treatment or guideline-based 
therapy [1, 2]. us, the discussion of this issue may contribute 
to an improvement of the clinical practice.
e main limitations of our study were the retrospective 
profile and sample size (however, this is a rare pathology and 
not all patients are indicated for HBOT). Aspects to highlight 
are: the inclusion of CRAO and BRAO cases, considering that 
most studies include only CRAO cases; and the great impact 
on clinical practice of this issue, whereas HBOT appears to be 
a promising therapeutic option in a pathology without an 
approved effective treatment and with a bad visual prognosis 
according to its natural history.
To conclude, HBOT may improve the BCVA in patients 
with RAO when it is provided in the first 24 h aer the onset 
of symptoms. Further studies with more patients are necessary 
to better analyze the value and safety of HBOT in the treatment 
of RAO, as well as the exact “time window” to perform it.
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